Literature DB >> 20124431

Oncostatin M is a potent inducer of hepcidin, the iron regulatory hormone.

Bomee Chung1, Frédérique Verdier, Pavle Matak, Jean-Christophe Deschemin, Patrick Mayeux, Sophie Vaulont.   

Abstract

Erythropoietic activity is known to affect iron homeostasis through regulation of the liver iron regulatory hormone hepcidin. To identify new factors secreted by the erythroblasts that could influence hepcidin synthesis, we set up a coculture model. HuH7 hepatoma cells cocultured with primary human erythroblasts or erythroleukemic UT7 cells presented a 20- to 35-fold increase of hepcidin gene expression. This induction was fully blunted in the presence of a neutralizing oncostatin M antibody, demonstrating that this cytokine, belonging to the IL-6 family of cytokines, was responsible for increased levels of hepcidin expression. We further demonstrated that recombinant oncostatin M induced a dramatic transcriptional increase of hepcidin in HuH7 cells through specific activation of the STAT pathway. Hepcidin induction by oncostatin M was also observed in hepatocytes in primary culture and is believed to be cell specific since no induction was found in isolated bone marrow cells, macrophagic, stromal, and lymphoma-derived cell lines, nor in erythroblasts. Finally, we show that oncostatin M administration in vivo increases hepcidin expression and leads to significantly decreased serum iron levels. This work identifies a new potent inducer of hepcidin expression in the liver and supports a role for modulators of oncostatin M signaling pathway in treating iron disorders.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20124431     DOI: 10.1096/fj.09-152561

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  22 in total

1.  A tincture of hepcidin cures all: the potential for hepcidin therapeutics.

Authors:  Thomas B Bartnikas; Mark D Fleming
Journal:  J Clin Invest       Date:  2010-11-22       Impact factor: 14.808

2.  Peginesatide and erythropoietin stimulate similar erythropoietin receptor-mediated signal transduction and gene induction events.

Authors:  Jennifer M Green; Karen Leu; Angela Worth; Richard B Mortensen; David K Martinez; Peter J Schatz; Don M Wojchowski; Peter R Young
Journal:  Exp Hematol       Date:  2012-03-06       Impact factor: 3.084

3.  Defining an EPOR- regulated transcriptome for primary progenitors, including Tnfr-sf13c as a novel mediator of EPO- dependent erythroblast formation.

Authors:  Seema Singh; Arvind Dev; Rakesh Verma; Anamika Pradeep; Pradeep Sathyanarayana; Jennifer M Green; Aishwarya Narayanan; Don M Wojchowski
Journal:  PLoS One       Date:  2012-07-13       Impact factor: 3.240

Review 4.  Regulation of the Iron Homeostatic Hormone Hepcidin.

Authors:  Veena Sangkhae; Elizabeta Nemeth
Journal:  Adv Nutr       Date:  2017-01-17       Impact factor: 8.701

5.  Effects of a single dose of oral iron on hepcidin concentrations in human urine and serum analyzed by a robust LC-MS/MS method.

Authors:  Sun-Il Hwang; Yong-Yook Lee; Jung-Ok Park; H James Norton; Elene Clemens; Laura W Schrum; Herbert L Bonkovsky
Journal:  Clin Chim Acta       Date:  2011-08-16       Impact factor: 3.786

6.  Glycol-split nonanticoagulant heparins are inhibitors of hepcidin expression in vitro and in vivo.

Authors:  Maura Poli; Michela Asperti; Annamaria Naggi; Natascia Campostrini; Domenico Girelli; Michela Corbella; Marina Benzi; Celine Besson-Fournier; Helene Coppin; Federica Maccarinelli; Dario Finazzi; Paolo Arosio
Journal:  Blood       Date:  2014-01-07       Impact factor: 22.113

Review 7.  The role of hepcidin and iron homeostasis in atherosclerosis.

Authors:  Florian Wunderer; Lisa Traeger; Haakon H Sigurslid; Patrick Meybohm; Donald B Bloch; Rajeev Malhotra
Journal:  Pharmacol Res       Date:  2020-01-25       Impact factor: 7.658

8.  Iron-deficiency anemia from matriptase-2 inactivation is dependent on the presence of functional Bmp6.

Authors:  Anne Lenoir; Jean-Christophe Deschemin; Léon Kautz; Andrew J Ramsay; Marie-Paule Roth; Carlos Lopez-Otin; Sophie Vaulont; Gaël Nicolas
Journal:  Blood       Date:  2010-10-12       Impact factor: 22.113

9.  Ferroportin and erythroid cells: an update.

Authors:  Luciano Cianetti; Marco Gabbianelli; Nadia Maria Sposi
Journal:  Adv Hematol       Date:  2010-08-11

Review 10.  Manipulation of the hepcidin pathway for therapeutic purposes.

Authors:  Eileen Fung; Elizabeta Nemeth
Journal:  Haematologica       Date:  2013-11       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.